Breaking News on Global Pharmaceutical Technology & Manufacturing

Processing: Top Headlines

Amgen to slash 23% of its manufacturing footprint and 2,900 US jobs

30-Jul-2014 - Amgen is slashing 15% of its workforce and closing two US manufacturing facilities as part of a restructure the firm says will save $700m (€520m) a year.

Related news

News in brief

Biocon: Political turmoil hits sales, but quality systems ensure future

29-Jul-2014 - Robust quality systems differentiate Biocon from other Indian manufacturers, the firm says, despite political turmoil in the Middle East and North Africa impacting first quarter 2015 sales.

Waters broadens mass spec offering with REIMS acquisition

29-Jul-2014 - Analytic science company Waters has acquired all of the assets of MediMass, which includes its Rapid Evaporative Ionization Mass Spectrometry (REIMS) technology, as well as patent applications, software, databases and REIMS expertise.

Lilly swaps dry powders for insulin at Indiana site in post-patent shake-up

23-Jul-2014 - Patent expiration and a large molecule pipeline has prompted Eli Lilly to repurpose a solid oral dose plant in Indiana.

Allergan further fends off Valeant with 1,500 job cuts, M&A projections

22-Jul-2014 - Botox maker Allergan announced sales and earnings per share growth above the high end of its expectations, but it will cut 1,500 jobs, or about 13% of its workforce as it continues to avoid a $54bn hostile takeover bid from Valeant Pharmaceuticals.

Glenmark to build first US manufacturing plant

21-Jul-2014 - India-based Glenmark Pharmaceuticals has announced plans to set up a new oral solid dosage manufacturing facility in North Carolina. 

Codexis: $25m GSK tech accord could be catalyst for more Big Pharma deals

15-Jul-2014 - Biocatalyst developer Codexis says its new platform licensing deal with GSK is a model with which it can approach other Big Pharma firms.

Pfizer: Unexpected hike in volumes of post-patent drugs saves Irish jobs

11-Jul-2014 - Pfizer says 100 workers at an Irish facility will now keep their jobs due to an unpredicted increase in production volumes of off-patent drugs.

Processing: Featured news

Spotlight

G-CON: Pfizer investment an endorsement of 'podular' manufacturing

Pfizer investment an endorsement of 'podular' manufacturing, says G-CON

G-CON says a multi-million dollar investment by Pfizer could hasten the “paradigm shift” in pharma manufacturing towards...

US FDA enforcement evolving in India will drive compliance costs

Indian firms must invest in compliance as USFDA ups enforcement, says S&P

Indian drugmakers must invest heavily in compliance processes in response to the US FDA’s “aggressive surveillance” and...

Ease regulations to cure drug industry antibiotic resistance, says RPS

Ease regulations to cure drug industry antibiotic resistance, says RPS

The current model of antibiotic development “is broken,” says the Professor of Pharmaceutical Innovation at Kings College,...

Zogenix adds abuse deterrents to Zohydro painkiller

Zogenix adds abuse deterrents to Zohydro painkiller

Zogenix has modified its much-debated painkiller Zohydro with abuse-deterrent formulations.

Afrezza approval: Validation for Mannkind's drug and delivery tech

Afrezza approval: US FDA validation for Mannkind's drug and delivery tech

The US FDA approved Afrezza last weekend after deeming that the inhaled insulin drug and the dry...

Key Industry Events

 

Access all events listing

Our events, Events from partners...